NCT00227617 2023-05-22
Combination Chemotherapy and Bevacizumab in Treating Patients With Advanced Neuroendocrine Tumors
University of California, San Francisco
Phase 2/3 Terminated
University of California, San Francisco
Incyte Corporation
Gilead Sciences
Western Regional Medical Center
National Institutes of Health Clinical Center (CC)